Enhanced Glioblastoma Immunotherapy via SMAC Mimetic Dose Escalation and TGFβ Blockade
Abstract Background Glioblastoma (GBM) is the most common primary brain tumor with an overall survival under 21 months. Despite extensive research effort, patient outcomes have ...